ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Phase 3 Study of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint
July 06, 2017Bristol-Myers Squibb announced a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection met its primary endpoint at a plann
Pharma Sources Insight January 2025
